TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) just unveiled an update.
Hemogenyx Pharmaceuticals has secured £250,000 to continue its Phase 1 clinical trials for its Chimeric Antigen Receptor T-cell therapy aimed at treating relapsed/refractory acute myeloid leukemia in adults. This funding, raised through an allotment to CEO Vladislav Sandler, reflects investor confidence in the company’s progress and potential, as evidenced by the premium issue price of the shares.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded clinical stage biopharmaceutical company based in London, with subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, utilizing several distinct product candidates and platform technologies.
Average Trading Volume: 37,697
Technical Sentiment Signal: Sell
Current Market Cap: £7.71M
For an in-depth examination of HEMO stock, go to TipRanks’ Overview page.